393 related articles for article (PubMed ID: 31733155)
1. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Okazuka K; Ishida T; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Suzuki K
Eur J Haematol; 2020 Feb; 104(2):110-115. PubMed ID: 31733155
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis.
Suzuki K; Tsukada N; Nishimura N; Nagata Y; Okazuka K; Mishima Y; Yokoyama M; Nishiwaki K; Ishida T; Yano S; Terui Y; Suzuki K
Int J Hematol; 2020 Jan; 111(1):103-111. PubMed ID: 31673952
[TBL] [Abstract][Full Text] [Related]
4. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
5. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
[TBL] [Abstract][Full Text] [Related]
6. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
10. [Efficacy and safety of VRD regimen of autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma].
Yan S; Jin S; Wang PF; Yan LZ; Shang JJ; Shi XL; Wu XJ; Zhai YY; Yao WQ; Wang J; Yao Y; Fu CC
Zhonghua Nei Ke Za Zhi; 2023 Jul; 62(7):819-825. PubMed ID: 37394852
[No Abstract] [Full Text] [Related]
11. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Rosiñol L; Oriol A; Rios R; Sureda A; Blanchard MJ; Hernández MT; Martínez-Martínez R; Moraleda JM; Jarque I; Bargay J; Gironella M; de Arriba F; Palomera L; González-Montes Y; Martí JM; Krsnik I; Arguiñano JM; González ME; González AP; Casado LF; López-Anglada L; Paiva B; Mateos MV; San Miguel JF; Lahuerta JJ; Bladé J
Blood; 2019 Oct; 134(16):1337-1345. PubMed ID: 31484647
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
[TBL] [Abstract][Full Text] [Related]
13. Adjusted Indirect Treatment Comparison of Progression-Free Survival with D-Rd and VRd Based on MAIA and SWOG S0777 Individual Patient-Level Data.
Durie BGM; Kumar SK; Ammann EM; Fu AZ; Kaila S; Lam A; Usmani SZ; Facon T
Adv Ther; 2024 May; 41(5):1923-1937. PubMed ID: 38494542
[TBL] [Abstract][Full Text] [Related]
14. Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.
Sidiqi MH; Aljama MA; Bin Riaz I; Dispenzieri A; Muchtar E; Buadi FK; Warsame R; Lacy MQ; Dingli D; Leung N; Gonsalves WI; Kapoor P; Kourelis TV; Hogan WJ; Rajkumar SV; Kumar SK; Gertz MA
Blood Cancer J; 2018 Nov; 8(11):106. PubMed ID: 30409963
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood stem cell mobilisation following bortezomib, lenalidomide and dexamethasone induction for multiple myeloma: a real-world single-centre experience.
Sim S; Quach H; Pham T; Smooker V; Filshie R
Intern Med J; 2024 Jan; 54(1):108-114. PubMed ID: 37357752
[TBL] [Abstract][Full Text] [Related]
16. Impact of Induction Therapy with VRD versus VCD on Outcomes in Patients with Multiple Myeloma in Partial Response or Better Undergoing Upfront Autologous Stem Cell Transplantation.
Sidana S; Kumar S; Fraser R; Estrada-Merly N; Giralt S; Agrawal V; Anderson LD; Aljurf M; Banerjee R; Bashey A; Battiwalla M; Beitinjaneh A; Chakraborty R; Chhabra S; Dhakal B; Dholaria B; Hashmi S; Janakiram M; Lee C; Lekakis L; Murthy HS; Parrondo R; Wangjam T; Usmani S; Shah N; Qazilbash M; D'Souza A
Transplant Cell Ther; 2022 Feb; 28(2):83.e1-83.e9. PubMed ID: 34781066
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide, bortezomib and dexamethasone followed by tandem- autologous stem cell transplantation is an effective treatment modality for multi-hit multiple myeloma.
Tang S; Lu Y; Zhang P; Chen D; Liu X; Du X; Cao J; Ye P; Chen L; Li S; Sha K; Zhuang XX; Xie Y; Wu X; Pei R
Leuk Res; 2021 Nov; 110():106710. PubMed ID: 34619433
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
O'Donnell EK; Laubach JP; Yee AJ; Chen T; Huff CA; Basile FG; Wade PM; Paba-Prada CE; Ghobrial IM; Schlossman RL; Burke JN; Harrington CC; Lively KJ; Lyons HF; Munshi NC; Anderson KC; Trippa L; Richardson PG; Raje NS
Br J Haematol; 2018 Jul; 182(2):222-230. PubMed ID: 29740809
[TBL] [Abstract][Full Text] [Related]
19. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma.
Cook J; Johnson I; Higgins A; Sidana S; Warsame R; Gonsalves W; Gertz MA; Buadi F; Lacy M; Kapoor P; Dispenzieri A; Kourelis T; Dingli D; Fonder A; Hayman S; Hobbs M; Hwa YL; Kyle R; Leung N; Go R; Rajkumar VS; Kumar S
Am J Hematol; 2021 Mar; 96(3):330-337. PubMed ID: 33326116
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.
Ocio EM; Perrot A; Bories P; San-Miguel JF; Blau IW; Karlin L; Martinez-Lopez J; Wang SY; Bringhen S; Marcatti M; Mateos MV; Rodriguez-Otero P; Oliva S; Nogai A; Le Roux N; Dong L; Macé S; Gassiot M; Fitzmaurice T; Oprea C; Moreau P
Leukemia; 2023 Jul; 37(7):1521-1529. PubMed ID: 37316728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
